%0 Journal Article
%T Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)
%A Eilon D Kirson
%A Rosa S Schneiderman
%A Vladim¨ªr Dbaly
%A Franti£¿ek Tovary£¿
%A Josef Vymazal
%A Aviran Itzhaki
%A Daniel Mordechovich
%A Zoya Gurvich
%A Esther Shmueli
%A Dorit Goldsher
%A Yoram Wasserman
%A Yoram Palti
%J BMC Medical Physics
%D 2009
%I BioMed Central
%R 10.1186/1756-6649-9-1
%X Cell proliferation in culture was studied in human breast carcinoma (MDA-MB-231) and human glioma (U-118) cell lines, exposed to TTFields, paclitaxel, doxorubicin, cyclophosphamide and dacarbazine (DTIC) separately and in combinations. In addition, we studied the effects of combining chemotherapy with TTFields in an animal tumor model and in a pilot clinical trial in recurrent and newly diagnosed GBM patients.The efficacy of TTFields-chemotherapy combination in-vitro was found to be additive with a tendency towards synergism for all drugs and cell lines tested (combination index ¡Ü 1). The sensitivity to chemotherapeutic treatment was increased by 1¨C3 orders of magnitude by adjuvant TTFields therapy (dose reduction indexes 23 ¨C 1316). Similar findings were seen in an animal tumor model. Finally, 20 GBM patients were treated with TTFields for a median duration of 1 year. No TTFields related systemic toxicity was observed in any of these patients, nor was an increase in Temozolomide toxicity seen in patients receiving combined treatment. In newly diagnosed GBM patients, combining TTFields with Temozolomide treatment led to a progression free survival of 155 weeks and overall survival of 39+ months.These results indicate that combining chemotherapeutic cancer treatment with TTFields may increase chemotherapeutic efficacy and sensitivity without increasing treatment related toxicity.A new physical cancer treatment modality termed Tumor Treating Fields, or TTFields, has recently been demonstrated to be highly effective when applied to cell cultures, animal cancer models, as well as to patients suffering from locally advanced and or metastatic solid tumors [1-3]. In a pilot clinical trial, the medians of time to disease progression and overall survival of recurrent GBM patients treated by TTFields alone were more than double the reported medians of historical control patients [1]. In contrast to the widely used physical treatment modality, ionizing radiation, TTFields are
%U http://www.biomedcentral.com/1756-6649/9/1